Viking Global Investors
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies.
Business Model:
Revenue: $15M
Employees: 51-200
Rankings
Industries / Tags:
Detailed Viking Global Investors Information
Geographic Data
Address: 55 Railroad Avenue
City: Greenwich
State: CT
Zip: 06830
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
1,562,596Website Global Rank
16,000Website Monthly Traffic
Twitter Followers
Description
Viking Global Investors is an investment firm that uses fundamental analysis to select investments across industries and geographies. It is a global investment firm managing more than twenty billion in capital across long-short equity and long-only strategies. The firm was established in 1999 and is headquartered in Greenwich, Connecticut, with offices in New York City, Hong Kong, and London.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2020 | Kinnate Biopharma | Series C | 98M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2020 | Athira Pharma | Series B | 85M |
| 6/2016 | Ginkgo Bioworks | Series C | 0 |
| 3/2021 | Ecovative Design | Series D | 60M |
| 4/2021 | Atlast Food | Series A | 40M |
| 7/2020 | VelosBio | Series B | 137M |
| 10/2020 | Talaris Therapeutics | Series B | 0 |
| 5/2021 | Nuvalent | Series B | 0 |
| 6/2021 | RayzeBio | Series C | 108M |
| 6/2021 | Iterable | Series E | 0 |
| 7/2021 | Amylyx Pharmaceuticals | Series C | 0 |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 10/2019 | Algen Biotechnologies | Pre Seed Round | - |
| 2/2018 | Moderna Therapeutics | Series G | 0 |
| 12/2020 | Boost Biomes | Series A | 2M |
| 11/2007 | Vivacta | Series B | 12M |
| 6/2017 | Deciphera Pharmaceuticals | Series C | 52M |
| 3/2020 | AbCellera Biologics | Series A | 75M |
| 5/2023 | Lightmatter | Series C | 0 |
| 10/2021 | Global Processing Services | Private Equity Round | 300M |
| 3/2021 | Amunix | Series B | 117M |
| 6/2019 | Druva | Series G | 0 |
| 2/2020 | Polaris Genomics | Seed Round | 2M |
| 3/2019 | Astarte Medical | Series A | 0 |
| 4/2018 | Eidos Therapeutics | Series B | 0 |
| 11/2021 | Cloudbeds | Series D | 0 |
| 4/2021 | Druva | Series H | 147M |
| 5/2020 | AbCellera | Series B | 105M |
| 9/2019 | Ginkgo Bioworks | Series E | 0 |
| 5/2020 | Ginkgo Bioworks | Series F | 70M |
| 10/2020 | Dock | Private Equity Round | 170M |
| 6/2015 | Credit Karma | Series E | 175M |
| 7/2020 | Mantra Bio | Series A | 25M |
| 1/2021 | Color | Series D | 167M |
| 5/2019 | Impossible Foods | Series E | 300M |
| 9/2017 | Joyn Bio | Series A | 0 |
| 3/2018 | Joyn Bio | Series A | 0 |
| 8/2019 | MedAnswers | Seed Round | 5M |
| 3/2020 | Impossible Foods | Series F | 500M |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 3/2019 | Mediphage Bioceuticals | Convertible Note | 3.5M |
| 12/2017 | Ginkgo Bioworks | Series D | 0 |
| 1/2021 | Resilient Biotics | Series A | 7.2M |
| 10/2018 | Genomatica | Equity | 90M |
| 4/2014 | Adaptive Biotechnologies | Series C | 5M |
| 12/2021 | DermBiont | Series A | 0 |
| 5/2020 | Apeel Sciences | Series D | 0 |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 4/2014 | Birchbox | Series B | 60M |
| 6/2018 | Checkerspot | Seed Round | 5M |
| 7/2016 | Roivant Sciences | Private Equity Round | 500M |
| 6/2021 | Motif | Series B | 0 |
| 8/2019 | Motif | Series A | 27.5M |
| 7/2018 | Apeel Sciences | Series C | 70M |
| 8/2021 | Apeel Sciences | Series E | 0 |
| 8/2021 | Biome Makers | Series B | 0 |
| 11/2016 | Prospect Bio | Seed Round | 0 |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 6/2023 | Ecovative Design | Series E | 30M |
| 4/2019 | NextGen Jane | Series A | 9M |
| 10/2016 | Biome Makers | Seed Round | 2.2M |
| 12/2019 | Iterable | Series D | 60M |
| 10/2022 | Arctic Wolf | Convertible Note | 401M |
| 6/2020 | 4D Molecular Therapeutics | Series C | 0 |
| 7/2017 | Vets First Choice | Private Equity Round | 223M |
| 10/2020 | Arctic Wolf | Series E | 200M |
| 6/2019 | DermBiont | Series A | 0 |
| 8/2017 | Auris Health | Series D | 0 |
| 10/2021 | Arcaea | Series A | 78M |
| 12/2017 | Zentalis Pharmaceuticals | Series B | 34M |
| 11/2018 | Auris Health | Series E | 0 |
| 4/2023 | AlphaSense | Series D | 100M |
| 9/2017 | BridgeBio Pharma | Series C | 135M |
| 12/2019 | Zentalis Pharmaceuticals | Series C | 85M |
| 3/2021 | ID.me | Series C | 0 |
| 4/2020 | Rallybio | Series B | 0 |
| 4/2023 | ID.me | Series D | 0 |
| 9/2021 | AlphaSense | Series C | 180M |
| 2/2020 | TruGenomix | Seed Round | 0 |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
| 9/2021 | Astarte Medical | Series A | 0 |
| 6/2021 | Clip | Series D | 250M |
| 6/2021 | PROCEPT BioRobotics | Series G | 0 |
| 10/2020 | Allonnia | Series A | 40M |
| 2/2017 | Xcell Biosciences | Series A | 12M |
| 6/2009 | Vivacta | Venture Round | 4.5M |
| 8/2021 | Algen Biotechnologies | Seed Round | - |
| 2/2018 | PROCEPT BioRobotics | Series E | 0 |
| 10/2021 | Patina | Series A | 50M |
| 1/2020 | Color | Series D | 75M |
| 1/2023 | Mantra Bio | Series A | 9M |
| 4/2022 | Revenova | Venture Round | 0 |
| 4/2014 | Adaptive Biotechnologies | Series D | 100M |
| 8/2017 | aTyr Pharma | Post-IPO Equity | 45M |
| 7/2015 | Ginkgo Bioworks | Series B | 0 |
| 11/2020 | VastBiome | Seed Round | 4.5M |
| 8/2021 | Talkdesk | Series D | 230M |
| 3/2020 | Cloudbeds | Series C | 0 |
| 11/2020 | Pharvaris | Series C | 80M |
| 10/2020 | LianBio | Series A | 0 |
| 4/2019 | Checkerspot | Series A | 13M |
| 2/2016 | Vitagene | Seed Round | 2M |
| 5/2019 | Inhibrx | Private Placement | 40M |
| 10/2020 | Solarea Bio | Series A | 11.2M |
| 12/2020 | Edgewise Therapeutics | Series C | 95M |
| 7/2021 | Arctic Wolf | Series F | 150M |
| 7/2021 | Sema4 | Post-IPO Equity | 350M |
| 5/2023 | Solarea Bio | Series B | 0 |
| 5/2022 | Dock | Private Equity Round | 0 |
| 7/2020 | Talkdesk | Series C | 143M |
| 8/2020 | PMV Pharmaceuticals | Series D | 70M |
| 7/2016 | Trace Genomics | Seed Round | 4M |
| 10/2018 | Talkdesk | Series B | 100M |
| 10/2021 | Roivant Sciences | Post-IPO Equity | 0 |
| 4/2020 | Affinivax | Series B | 120M |
| 6/2021 | Antheia | Series B | 0 |
| 6/2020 | HeadLight | Series B | 25.6M |
| 8/2021 | Pepgen | Venture Round | 0 |
| 9/2022 | RayzeBio | Series D | 160M |
| 11/2018 | Roivant Sciences | Private Equity Round | 0 |
| 1/2021 | Affinivax | Series C | 226M |
| 12/2022 | Pearl Health | Series B | 0 |
| 6/2017 | Yes To | Equity | 56M |
| 6/2019 | Viela Bio | Series B | 0 |
| 9/2018 | 4D Molecular Therapeutics | Series B | 0 |
| 7/2021 | Genomatica | Series C | 0 |
| 2/2021 | Ensoma | Series A | 0 |
| 11/2021 | Color | Series E | 100M |
| 1/2015 | Moderna Therapeutics | Series E | 0 |
| 1/2022 | Xcell Biosciences | Series B | 27.5M |
| 8/2021 | Zentera Therapeutics | Series B | 75M |
| 2/2018 | Boost Biomes | Seed Round | 2M |
| 2/2021 | Day One Biopharmaceuticals | Series B | 130M |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 12/2022 | Vector Biomed | Venture Round | 15M |
| 6/2022 | AlphaSense | Series D | 225M |
| 10/2021 | Groove | Series B | 45M |
| 4/2021 | Lightmatter | Series B | 80M |
| 5/2020 | Checkerspot | Series B | 36M |
| 1/2023 | Ensoma | Series B | 0 |
| 2/2016 | EpiBiome | Series A | 6M |
| 1/2023 | SetPoint Medical | Venture Round | 0 |
| 4/2021 | Icosavax | Series B | 0 |
| 9/2015 | Impossible Foods | Series D | 108M |
| 8/2015 | Editas Medicine | Series B | 0 |
| 6/2022 | AlphaSense | Series D | 0 |
| 5/2022 | Locus Biosciences | Series B | 0 |
| 5/2022 | Dock | Private Equity Round | 0 |
| 4/2022 | Revenova | Venture Round | 0 |
| 2/2022 | Cazoo | Post-IPO Debt | 0 |
| 1/2022 | Standard BioTools | Post-IPO Equity | 0 |
| 1/2022 | Xcell Biosciences | Series B | 0 |
| 1/2022 | Cognism | Series C | 0 |
| 12/2021 | DermBiont | Series A | 0 |
| 12/2021 | Mythic Therapeutics | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
